Enanta Pharmaceuticals

Enanta receives additional $9.2m funding from NIAID

Wednesday, September 4, 2013

The National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH, has agreed to provide additional funding of $9.2 million to its existing contract with Enanta Pharmaceuticals, an R&D-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, to fund preclinical and early clinical development for a new class of bridged bicyclic antibiotics known as Bicyclolides.

[Read More]